Chronic Pain - Market Insights, Epidemiology, and Forecast 2034: Embracing Multimodal and Non-Opioid Therapeutic Strategies | DelveInsight

Chronic pain, defined as persistent or recurrent pain lasting longer than three months, is a widespread and debilitating condition impacting physical, emotional, and social well-being. It spans multiple etiologies-including neuropathic, musculoskeletal, inflammatory, and cancer-related pain-and affects millions globally, making it one of the leading causes of disability and healthcare burden worldwide. Common chronic pain conditions include fibromyalgia, lower back pain, osteoarthritis, diabetic neuropathy, and migraine.

The management of chronic pain has long relied on pharmacologic interventions, particularly opioids, NSAIDs, antidepressants, and anticonvulsants. However, growing concerns over opioid dependency, limited long-term efficacy, and adverse effects have prompted a major shift toward non-opioid, multimodal, and targeted therapies. Innovations in neuromodulation, regenerative medicine, biologics, and digital therapeutics are transforming the chronic pain treatment landscape.

DelveInsight's in-depth report, Chronic Pain - Market Insight, Epidemiology, and Market Forecast - 2034, provides a robust analysis of the current and evolving market dynamics. The report offers detailed epidemiological insights segmented by pain type, severity, age, gender, and comorbidities across key geographies, including the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan. It also evaluates the current standard of care, unmet clinical needs, treatment algorithms, and the expanding pipeline of emerging therapies.

With increasing focus on patient-centric care, regulatory support for non-opioid alternatives, and the integration of AI and digital health tools in pain management, the chronic pain market is poised for steady expansion and innovation through 2034, promising more personalized, effective, and safer solutions for long-suffering patients.

Request a sample and uncover the latest breakthroughs shaping the chronic pain market landscape and future outlook @ https://www.delveinsight.com/report-store/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Chronic Pain Market Report:
• The chronic pain market is expected to grow significantly through the forecast period (2024-2034).
• In 2023, the total diagnosed chronic pain cases in the 7MM were approximately 114.4 million, expected to grow moderately by 2034.
• The US had the highest prevalence, with about 36.2 million cases, projected to rise by 2034.
• In the US, the 45-64 age group had the highest number of diagnosed cases (~2.2 million), while those ≥85 years had the least.
• Mild cases accounted for around 11 million, while moderate to severe cases were about 25 million in 2023.
• In January 2025, Zynex Inc. expanded its portfolio of non-invasive medical devices for pain management and rehabilitation. The FDA recently cleared Zynex's TensWave device, which uses Transcutaneous Electrical Nerve Stimulation (TENS) therapy for portable, drug-free pain relief. Zynex's flagship NexWave device, clinically proven to reduce chronic pain, combines multiple therapeutic modalities for effective pain management.
• In September 2024, Nevro Corp., a leading global medical device company focused on delivering transformative solutions for chronic pain management, announced the FDA approval and limited market release of the HFX iQTM system, featuring HFX AdaptivAITM. This advanced, responsive pain management platform enhances the HFX iQ spinal cord stimulation (SCS) system.
• Emerging therapies for chronic pain include ZILOSUL, HP-5000, GSK3858279, and others.
• Key companies involved in the treatment of chronic pain include AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.

To know in detail about the chronic pain market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/report-store/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chronic Pain Overview
Chronic pain is a long-lasting condition characterized by pain that persists for more than three months, often continuing beyond the normal healing period. Unlike acute pain, which signals immediate injury or threat to the body, chronic pain may remain even after the original injury has healed or may arise without a clear cause. It can affect any part of the body and varies in intensity, duration, and impact. Common conditions associated with chronic pain include arthritis, fibromyalgia, neuropathic pain, migraines, and lower back pain.

This condition significantly disrupts daily life, often leading to sleep disturbances, reduced physical activity, anxiety, depression, and social withdrawal. It may stem from known medical conditions or injuries, but in many cases, the underlying cause remains unclear, making diagnosis and treatment challenging. Factors such as aging, sedentary lifestyles, previous injuries, and certain genetic predispositions can increase the risk of developing chronic pain.

Management of chronic pain typically involves a multidisciplinary approach that includes medications, physical therapy, psychological support, and lifestyle modifications. In some cases, interventional procedures or neuromodulation techniques may be recommended. Given its complex and multifactorial nature, chronic pain remains a major public health concern and a leading cause of long-term disability worldwide.

Get a free sample for the chronic pain market forecast, size & share analysis report: https://www.delveinsight.com/report-store/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chronic Pain Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Chronic Pain Epidemiology Segmentation:
The Chronic Pain market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total Chronic Pain Prevalent Cases
• Total Chronic Pain Diagnosed Cases
• Total Chronic Pain Age-specific Cases
• Chronic Pain Cause-specific Cases
• Chronic Pain Severity-specific Cases
• Total Chronic Pain Treated Cases

Chronic Pain Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for chronic pain throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the chronic pain drugs demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for chronic pain, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of chronic pain therapeutics.

Explore how emerging chronic pain therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chronic Pain Market Outlook
Chronic pain is a major public health concern affecting millions globally and contributing to significant physical, emotional, and socioeconomic burdens. The management of chronic pain requires a comprehensive, multimodal strategy involving pharmacological, interventional, rehabilitative, and behavioral approaches. Pharmacotherapy remains central to treatment, especially for moderate to severe cases, with nonopioid and opioid medications forming the primary categories. The focus is increasingly shifting towards minimizing opioid reliance by integrating other modalities to reduce dependency risks and improve long-term outcomes.

Interventional pain management, including nerve blocks, spinal injections, and neuromodulation techniques, plays a critical role in alleviating pain while limiting systemic drug exposure. These procedures are often combined with physical and occupational therapy to restore function and mobility. Movement-based therapies and physiotherapy are key components of interdisciplinary care, aiming to reduce pain through restorative activity and conditioning. Additionally, behavioral health interventions such as cognitive behavioral therapy (CBT) address the psychological and social dimensions of chronic pain, further enhancing patient outcomes.

Complementary and integrative health approaches are also gaining traction, offering non-pharmacologic alternatives that include acupuncture, massage, chiropractic manipulation, meditative movement therapies, and the use of natural products. These modalities are increasingly adopted within multidisciplinary care models to support a more holistic approach to chronic pain management.

On the market front, innovation is being driven by the need for safer and more effective non-opioid therapies. The approval of multiple calcitonin gene-related peptide (CGRP) receptor antagonists marks a significant advancement in migraine treatment. In 2023, the FDA approved QULIPTA (atogepant) for preventive migraine care and ZAVZPRET (zavegepant) for acute migraine treatment, reflecting the trend toward targeted therapies. Teva's AJOVY (fremanezumab) and Daiichi Sankyo's TARLIGE (mirogabalin besylate) further expand the therapeutic landscape, addressing both migraine and peripheral neuropathic pain. These developments underscore the dynamic nature of the chronic pain market, with growing emphasis on precision therapies and comprehensive care frameworks.

Chronic Pain Market Drivers
• The rising prevalence of conditions like arthritis, migraines, and neuropathic pain, especially in aging populations, is increasing demand for long-term pain management solutions.
• Concerns over opioid misuse are driving the adoption of safer, non-opioid therapies and integrated, multidisciplinary treatment models, expanding market opportunities.

Chronic Pain Market Barriers
• Lengthy approval processes and limited insurance coverage for newer or integrative therapies can delay access and adoption.
• The subjective and complex nature of chronic pain leads to inconsistent treatment outcomes and a lack of standardized care pathways, limiting market growth.

Scope of the Chronic Pain Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Chronic Pain Companies: AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.
• Key Chronic Pain Therapies: ZILOSUL, HP-5000, GSK3858279, and others.
• Chronic Pain Therapeutic Assessment: Chronic Pain currently marketed, and Chronic Pain emerging therapies.
• Chronic Pain Market Dynamics: Chronic Pain market drivers and Chronic Pain market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Chronic Pain Unmet Needs, KOL's views, Analyst's views, Chronic Pain Market Access and Reimbursement.

To learn more about chronic pain companies working in the treatment market, visit @ https://www.delveinsight.com/report-store/chronic-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Chronic Pain Market Report Introduction
2. Executive Summary for Chronic Pain
3. SWOT analysis of Chronic Pain
4. Chronic Pain Patient Share (%) Overview at a Glance
5. Chronic Pain Market Overview at a Glance
6. Chronic Pain Disease Background and Overview
7. Chronic Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Pain
9. Chronic Pain Current Treatment and Medical Practices
10. Chronic Pain Unmet Needs
11. Chronic Pain Emerging Therapies
12. Chronic Pain Market Outlook
13. Country-Wise Chronic Pain Market Analysis (2020-2034)
14. Chronic Pain Market Access and Reimbursement of Therapies
15. Chronic Pain Market Drivers
16. Chronic Pain Market Barriers
17. Chronic Pain Appendix
18. Chronic Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.